Open AccessLRH1 as a promising prognostic biomarker and predictor of metastasis in patients with non‐small cell lung cancer
Author(s) -
Liu Yuechao,
Xing Ying,
Wang Hongmei,
Yan Shi,
Wang Xinzhu,
Cai Li
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12887
Subject(s) - medicine , hazard ratio , adenocarcinoma , lung cancer , oncology , biomarker , immunohistochemistry , metastasis , stage (stratigraphy) , confidence interval , pathological , carcinoma , cancer , pathology , biology , paleontology , biochemistry
Background LRH1, which promotes the malignant transformation of carcinoma, has recently been documented in several types of malignancies. However, LRH1 has not been assessed as a potential clinical biomarker in any cancer. Methods LRH1 expression was tested in fresh‐frozen tissue samples with quantitative real‐time PCR and Western blot analysis. Surgically resected tumor tissues were collected from 156 non‐small cell lung cancer (NSCLC) patients: 75 with adenocarcinoma and 81 with squamous cell carcinoma. Subsequently, the immunohistochemical expression of LRH1 was examined, and its clinical significance was evaluated. Results LRH1 overexpression was observed in NSCLC carcinoma tissues compared to adjacent normal lung tissues. LRH1 expression was correlated with poorer differentiation ( P = 0.023), pathological tumor classification ( P < 0.001), advanced pathological tumor node metastasis stage ( P = 0.017), adenocarcinoma subtype ( P = 0.031), and positive lymph node metastasis ( P < 0.001). Multivariate analysis demonstrated that LRH1 expression status was an independent prognostic factor for overall (hazard ratio 1.372, 95% confidence interval 1.225–1.617; P = 0.003) and disease‐free survival (hazard ratio 1.497, 95% confidence interval 1.059–2.115; P = 0.011) in patients who suffered from resectable NSCLC. Conclusion The results of our study indicate that LRH1 predicts NSCLC progression, metastasis, and a dismal prognosis, emphasizing its promising role as a novel target in NSCLC therapies.